Cytology and Biomarkers in NMIBC
Cystoscopy and cytology remain the standard for diagnosis, but a plethora of urinary biomarkers could someday be a useful adjunct to NMIBC surveillance.
Bladder Cancer
FEATURES
Latest Bladder Cancer News
Bavencio Approved for First-Line Urothelial Carcinoma Maintenance Treatment
The FDA has approved Bavencio® (avelumab; EMD Serono) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Active Anticancer Treatment Associated With Poor COVID-19 Prognosis
Genome-wide association studies have revealed over 180 SNPs associated with increased breast cancer risk.
Study Finds No Associations Between HCV and Genitourinary Cancers
A team of investigators from the University of Texas MD Anderson Cancer Center assessed whether a relationship exists between hepatitis C virus infection and common genitourinary cancers, such as kidney and prostate cancer.
AUA Releases Updated Guidelines on Microhematuria, BPH-Related LUTS
The new guidance aims to support urologists and other clinicians in providing evidence-based care to their patients.
Avelumab Shown to Prolong Survival in Advanced Urothelial Carcinoma
Adding avelumab to best supportive care following chemo in advanced UC significantly improved OS compared with best supportive care alone.
Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBC
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Prioritizing Urologic Cancer Cases During the COVID-19 Pandemic
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
5-ARIs Do Not Lower Bladder Cancer Risk
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
High BMI in Childhood May Up Risk for Bladder Cancer as Adult
Height inversely linked to bladder cancer, while excess BMI gain in childhood linked to increased risk.
Atezolizumab Added to Chemo Delays Metastatic Bladder Cancer Progression
In a phase 3 trial, atezolizumab plus platinum-based chemotherapy as first-line treatment for metastatic urothelial carcinoma improved progression-free survival vs chemotherapy alone.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Bladder Cancer
